Generate Biomedicines Inc. (GENB), which recently debuted on the Nasdaq, continues to advance its clinical pipeline across multiple therapeutic areas, modalities, and both wholly owned and partnered programs. This clinical-stage generative biology company is pioneering the AI revolution in drug design and development.